Based on these findings, a Stage II clinical trial is at Wake Forest Baptist underway.. Agents targeting mitochondrial rate of metabolism can have activity in leukemia Results of a Phase I actually clinical trial showed a new medication targeting mitochondrial function in human being cancer cells was safe and sound and showed some efficacy. The results, reported by doctors at Wake Forest Baptist Medical Center, are published in today’s on the web edition of the journal Clinical Malignancy Research. This medication is selectively adopted by tumor cells and shuts down the production of energy in the mitochondria, stated Timothy Pardee, M.D., Ph.D., director of leukemia translational study at Wake Forest Baptist and principal investigator of the trial.In addition, we excluded subjects who have been younger than 18 years of age , those who had a BMI of more than 50 , and those for whom data on survival had been invalid or missing . After these exclusions, 1,141,609 subjects remained . Statistical Analysis The association between BMI and the risk of loss of life was analyzed with the use of Cox proportional-hazards regression models, with a categorical representation of BMI as the predictor variable. To define BMI groupings for the analysis, the BMI was utilized by us cutoff points greater than 25.0 for overweight and a lot more than 30.0 for obesity.0) and the best and 8 levels in between, each comprising 2.5 BMI units .